Skip to main content

Table 3 Antimicrobial susceptibility among Gram negative isolates including ESBL-producing strains from blood specimens collected between 2012 and 2016

From: Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial

  Africa Asia Europe North America Latin America Global Global
S% S% S% S% S% MIC90(mg/L) MIC range(mg/L) S% R% MIC90(mg/L) MIC range(mg/L) S% R%
  E.coli E.coli, all isolates E.coli ESBL isolates
N = 47 N = 396 N = 3235 N = 1487 N = 187 N = 5352 N = 852
Amikacin 97.9 97.7 99.5 99.9 98.9 4 0.5–128 99.4 0.2 8 0.5–64 98.4 0.2
Amoxy/clav 48.9 72.0 70.1 78.1 64.7 32 0.25–64 72.1 10.1 32 0.5–64 48.6 14.4
Ampicillin 12.8 18.4 32.8 43.4 26.2 64 0.5–64 34.3 65.0 64 1–64 0.6 99.4
Cefepime 57.5 59.6 82.0 88.8 73.8 16 0.5–64 81.8 13.1 64 0.5–64 13.9 64.7
Ceftazidime 63.8 70.0 86.5 91.6 79.1 8 1–32 86.3 9.4 32 1–32 35.3 42.7
Ceftriaxone 48.9 49.8 78.8 87.4 67.4 64 0.06–64 78.4 21.0 64 0.06–64 0.9 97.8
Levofloxacin 51.1 48.0 64.9 71.6 58.8 16 0.008–16 65.2 31.9 16 0.008–16 16.3 78.9
Meropenem 95.7 98.2 99.9 99.7 97.3 0.06 0.06–32 99.6 0.4 0.12 0.06–16 99.5 0.4
Minocycline 74.5 83.3 85.9 91.3 81.8 8 0.5–32 87.0 7.4 8 0.5–32 86.0 7.3
Pip/taz 80.9 95.0 92.7 97.4 94.4 8 0.06–256 94.1 3.2 16 0.06–256 91.2 4.5
Tigecycline 100 100 99.9 99.9 100 0.25 0.008–16 99.9 0.04 0.5 0.008–2 100 0.0
  K.pneumoniae K.pneumoniae, all isolates K.pneumoniae ESBL isolates
N = 52 N = 276 N = 1761 N = 899 N = 166 N = 3154 N = 659
Amikacin 84.6 90.2 96.7 99.4 96.4 8 0.5–128 96.7 1.8 16 0.5–128 95.8 2.7
Amoxy/clav 25.0 66.7 60.8 90.9 59.0 64 0.12–64 69.2 18.8 64 2–64 19.6 40.2
Ampicillin 1.8 2.2 2.6 6.2 1.2 64 0.5–64 3.5 85.1 64 16–64 0 99.9
Cefepime 34.6 66.7 65.0 93.3 57.2 64 0.5–64 72.3 23.4 64 0.5–64 8.4 78.0
Ceftazidime 34.6 69.2 67.0 91.2 68.7 32 1–32 73.6 21.7 32 1–32 18.1 65.0
Ceftriaxone 21.2 62.7 62.5 90.6 54.2 64 0.06–64 69.4 29.8 64 0.06–64 1.8 97.3
Levofloxacin 57.7 76.5 70.8 91.4 80.7 16 0.008–16 77.5 18.7 16 0.03–16 40.5 47.7
Meropenem 84.6 89.5 87.9 98.0 91.6 1 0.06–32 91.1 8.0 8 0.06–32 84.8 11.7
Minocycline 71.2 83.3 78.6 87.5 83.7 16 0.5–32 81.7 11.5 16 0.5–32 70.3 18.2
Pip/taz 55.8 80.8 76.7 94.1 77.1 256 0.06–256 81.7 15.0 256 0.5–256 59.6 29.1
Tigecycline 96.2 93.1 94.4 95.6 97.6 2 0.008–16 94.8 0.7 2 0.008–16 90.4 1.2
  S.marcescens  
N = 29 N = 88 N = 591 N = 224 N = 92 N = 1024  
Amikacin 100.0 96.6 99.0 100.0 85.9 4 0.5–128 97.9 0.9     
Amoxy/clav 0.0 8.0 3.1 1.3 3.3 64 0.5–64 3.0 92.4     
Ampicillin 0.0 6.8 6.3 4.0 4.4 64 0.5–64 5.5 87.3     
Cefepime 89.7 85.2 96.6 98.7 80.4 1 0.5–64 94.4 3.8     
Ceftazidime 96.6 88.6 96.1 98.2 87.0 2 1–32 95.1 3.8     
Ceftriaxone 89.7 79.6 85.3 88.0 71.7 4 0.06–64 84.3 11.8     
Levofloxacin 100.0 94.3 95.8 96.0 89.1 1 0.008–16 95.2 2.9     
Meropenem 96.6 95.5 99.0 99.1 93.5 0.25 0.06–32 98.1 1.6     
Minocycline 100.0 88.6 90.4 94.2 88.0 4 0.5–32 91.9 2.3     
Pip/taz 100.0 89.8 94.1 97.3 90.2 8 0.06–256 94.2 2.4     
Tigecycline 96.6 95.5 97.0 97.8 93.5 2 0.03–16 96.7 0.3     
  E.cloacae  
N = 47 N = 157 N = 1084 N = 404 N = 132 N = 1824  
Amikacin 95.7 96.8 99.0 100.0 97.0 4 0.5–128 98.8 0.9     
Amoxy/clav 2.1 1.9 3.7 3.0 1.5 64 0.12–64 3.2 95.4     
Ampicillin 4.3 3.2 6.8 4.5 4.6 64 0.5–64 5.8 89.5     
Cefepime 51.1 76.4 77.2 86.9 74.2 16 0.5–64 78.4 12.0     
Ceftazidime 51.1 63.1 65.0 74.5 65.9 32 1–32 66.7 29.6     
Ceftriaxone 40.4 59.2 59.7 70.5 60.6 64 0.06–64 61.6 36.2     
Levofloxacin 91.5 87.9 85.8 94.6 86.4 4 0.008–16 88.1 9.8     
Meropenem 100.0 94.3 97.2 99.5 97.7 0.25 0.06–32 97.6 1.6     
Minocycline 85.1 84.1 86.0 86.9 88.6 8 0.5–32 86.2 8.2     
Pip/taz 78.7 75.2 76.3 81.7 79.6 128 0.06–256 77.7 11.5     
Tigecycline 95.7 96.8 95.4 95.5 97.0 2 0.008–16 95.7 0.8     
  P.aeruginosa  
N = 29 N = 150 N = 1081 N = 387 N = 95 N = 1739     
Amikacin 96.6 95.3 94.3 97.9 88.4 8 0.5–128 94.9 2.7     
Cefepime 65.5 76.0 75.5 86.3 85.3 16 0.5–64 78.4 9.1     
Ceftazidime 79.3 77.3 78.8 88.9 82.1 32 1–32 81.1 11.4     
Levofloxacin 86.2 82.7 72.4 76.5 75.8 16 0.015–16 74.6 19.8     
Meropenem 75.9 69.3 69.6 75.7 69.5 16 0.06–32 71.1 22.0     
Pip/taz 82.8 78.0 78.3 86.8 85.3 64 0.12–256 80.7 7.9     
  A.baumannii     
N = 32 N = 123 N = 424 N = 118 N = 52 N = 749     
Amikacin 31.3 43.1 37.0 74.6 28.9 128 0.5–128 43.1 49.1     
Cefepime 12.5 27.6 24.1 54.2 15.4 64 0.5–64 28.3 65.7     
Ceftazidime 15.6 35.0 27.1 50.0 23.1 32 1–32 31.2 64.2     
Ceftriaxone 9.4 22.8 16.0 31.4 11.5 64 0.06–64 19.0 67.0     
Levofloxacin 21.9 30.9 23.6 51.7 15.4 16 0.008–16 28.6 61.7     
Meropenem 25.0 26.8 26.9 60.2 15.4 32 0.06–32 31.2 66.8     
Minocycline 81.3 73.2 61.8 89.0 90.4 8 0.5–32 70.8 8.8     
Pip/taz 12.5 26.0 24.5 52.5 13.5 256 0.06–256 27.9 68.2     
Tigecycline       2 0.008–4       
  1. Abbreviations: S% percentage of susceptible isolates, R% percentage of resistant isolates, MIC minimum inhibitory concentration, Amoxy/clav Amoxicillin/clavulanic acid, Pip/taz Piperacillin/tazobactam